This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Takeda Pharmaceutical Company Ltd
Drug Names(s): Kapidex, dexlansoprazole, TAK-390MROD
Description: TAK-390 is an enantiomer (one of two mirror-image molecules) of the proton pump inhibitor lansoprazole. It uses a dual delayed release delivery system that extends drug exposure and prolongs pH control compared with lansoprazole, and can be administered without regard to food or the timing of food.
Deal Structure: TAK-390MR is being developed by TAP Pharmaceutical Products, a joint venture of Abbott and Takeda.
In March 2008, Takeda Pharmaceutical and Abbott concluded their TAP Pharmaceutical Products (TAP) joint venture.
Partners: AbbVie Inc.
Pink Sheet Regulatory News In Brief
Additional information available to subscribers only: